Biomarkers of Progression and Risk Stratification in Asymptomatic Waldenstr öm Macroglobulinemia

Hematol Oncol Clin North Am. 2023 Aug 12:S0889-8588(23)00102-8. doi: 10.1016/j.hoc.2023.06.012. Online ahead of print.ABSTRACTWaldenström macroglobulinemia is an indolent IgM-secreting B-cell lymphoplasmacytic lymphoma that is preceded by an asymptomatic stage. Clinical and molecular features have been used in risk models to predict progression rates in different asymptomatic subgroups. Risk models used both disease-specific and nonspecific biomarkers for asymptomatic patients. Recently, models that incorporate continuous variables rather than distinct cutoffs have emerged to more accurately predict the risk of progression. Integrating genetic alterations to the clinical models is a promising approach that could improve risk stratification and management of asymptomatic patients.PMID:37574332 | DOI:10.1016/j.hoc.2023.06.012

Source: The Medical Clinics of North America - August 13, 2023 Category: General Medicine Authors: Mark Bustoros Caitlin Gribbin Jorge J Castillo Richard Furman Source Type: research